Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 12

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 12
---
80 and an expiration date of March 10, 2030 (the “Regulation A Warrants” and, together with the warrants and the Public Warrants, the “Warrants”). The aggregate gross proceeds to the Company from the Offering were $4,172,000.

The Company's registered and head office is located at One First Canadian Place, 100 King Street West, Suite 3400, Toronto, Ontario M5X 1A4, Canada.

We lease U.S. office space in Conshohocken, Pennsylvania to operate the businesses of our U.S. subsidiaries, Medicus Pharma Inc. and SkinJect, Inc.

Our website address is www.medicuspharma.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities.

<div align='center'>3</div>

Update on Phase 2 Clinical Study

On April 21, 2025, the Company announced that the Institutional Review Board approved the increase in the number of patients in its SKNJCT-003 Phase 2 clinical study from 60 to 90. The clinical study will expand from the nine clinical sites in the United States to include an additional site in the United States and two clinical trial sites in Europe. The Company also announced that it has randomized more than 45 participants in the study and is on track to submit the package seeking a Type C meeting with the FDA before the end of the second quarter of 2025.

Implications of Being an Emerging Growth Company

As a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an "emerging growth company" as that term is defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). As an emerging growth company we expect to take advantage of specified reduced reporting requirements that are otherwise applicable generally to public companies. These reduced reporting requirements include, but are not limited to:

•not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended ("Sarbanes-Oxley Act");

•reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and

•an exemption from the requirements to obtain a non-binding advisory vote on executive compensation or stockholder approval of any golden parachute arrangements.